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Aspartic proteases play key roles in the biology of malaria parasites and human immunodeficiency virus type
1 (HIV-1). We tested the activity of seven HIV-1 protease inhibitors against cultured Plasmodium falciparum.
All compounds inhibited the development of parasites at pharmacologically relevant concentrations. The most
potent compound, lopinavir, was active against parasites (50% inhibitory concentration [IC50], 0.9 to 2.1 M)
at concentrations well below those achieved by ritonavir-boosted lopinavir therapy. Lopinavir also inhibited the
P. falciparum aspartic protease plasmepsin II at a similar concentration (IC50, 2.7 M). These findings suggest
that use of HIV-1 protease inhibitors may offer clinically relevant antimalarial activity.
100 M to 25 nM) for 48 h beginning at the ring stage. The
effects of inhibitors upon P. falciparum morphology were assessed by light microscopy of Giemsa-stained smears. After
12 h of incubation, beginning at the late ring stage, synchronized parasites treated with concentrations of lopinavir achievable with standard dosing (10 M) exhibited markedly altered
morphology (Fig. 1A). Parasite abnormalities were more
marked after 24 h, and after 48 h, when control cultures contained normal rings, treated cultures contained only very abnormal pyknotic parasites. The morphological changes caused
by the protease inhibitors were rather nonspecific, but similar
to those caused by the generic aspartic protease inhibitor pepstatin (1, 10).
To quantify antimalarial activity, new ring stage parasites
were counted after incubating parasites with protease inhibitors for one 48-hour life cycle, beginning at the ring stage. Ring
parasitemias were assessed by fluorescence-activated cell
sorter analysis and compared with those of control cultures
incubated with the same concentration of DMSO, as previously described (11, 12). Fifty percent inhibitory concentrations (IC50s) were calculated by nonlinear regression with the
Prism 3.0 program (GraphPad Software). All tested HIV-1
protease inhibitors demonstrated antimalarial activity at low
micromolar concentrations (Table 1). Results were similar for
all four tested P. falciparum strains. Calulated IC50s were
higher than those previously reported for the HIV-1 protease
inhibitors saquinavir, ritonavir, and indinavir (13), probably
due to differences in assay methods, but nonetheless all tested
compounds exerted antimalarial activity at concentrations near
those achievable in the bloodstream with standard dosing. Importantly, combination regimens that take advantage of the
boosting of levels of other protease inhibitors by the strong
cytochrome P450 inhibitor ritonavir are increasingly advocated
for standard antiretroviral therapy (8). In this regard, it is of
interest that the most potent antimalarial protease inhibitor
was lopinavir, which demonstrated an IC50 nearly 10-fold below the trough blood concentration achieved with standard

The human immunodeficiency virus type 1 (HIV-1) pandemic has emerged in many regions of the developing world
already suffering from the burden of malaria (5). In developed
countries, HIV-1 protease inhibitors have dramatically improved the outcome of HIV disease. The target of these inhibitors is the HIV-1 protease, a member of the aspartic protease family (6). Plasmodium falciparum, the most virulent
human malaria parasite, expresses a number of aspartic proteases, known as plasmepsins (2). Recent studies suggest that
three HIV-1 protease inhibitors, saquinavir, ritonavir, and
indinavir, inhibit the growth of Plasmodium falciparum parasites in vitro at clinically relevant concentrations (13). In addition, evidence suggests that HIV-1 protease inhibitors may
protect against malaria through the inhibition of CD36-mediated cytoadherence of P. falciparum-infected erythrocytes (9).
We hypothesized that HIV-1 aspartic protease inhibitors exert
antimalarial activity by acting against plasmepsins. To test this
hypothesis, we investigated the effects of seven available HIV-1
protease inhibitors on the in vitro development of cultured
malaria parasites and on the P. falciparum aspartic protease
plasmepsin II.
To evaluate the antiparasitic effects of HIV-1 protease inhibitors, we incubated cultured parasites with multiple concentrations of seven inhibitors. P. falciparum parasites were cultured with human erythrocytes (2% hematocrit) in RPMI
medium and 10% human serum (11). Four laboratory strains
of P. falciparum (acquired from the Malaria Research and
Reference Reagent Center) with a wide range of sensitivities
to standard antimalarial drugs were studied (12). Parasites
were synchronized by serial treatments with 5% D-sorbitol
(11). Microwell cultures of synchronized parasites were incubated with HIV-1 protease inhibitors (from 1,000⫻ stocks in
dimethyl sulfoxide [DMSO]; final concentrations ranged from
* Corresponding author. Mailing address: University of California,
San Francisco, Box 0811, San Francisco, CA 94110. Phone: (415)
206-8687. Fax: (415) 648-8425. E-mail: sunil@itsa.ucsf.edu.
2983

Downloaded from http://aac.asm.org/ on March 8, 2014 by Washington University in St. Louis

Department of Medicine, San Francisco General Hospital, University of California, San Francisco, San Francisco,
California,1 and Department of Medicine and Department of Molecular Microbiology, Howard Hughes
Medical Institute, Washington University School of Medicine,
St. Louis, Missouri2

2984

NOTES

ANTIMICROB. AGENTS CHEMOTHER.

dosing of a lopinavir/ritonavir combination (Fig. 1B). Ritonavir
also demonstrated potent antimalarial activity at levels achievable with high dosages (600 mg twice daily [b.i.d.]), and at
lower dosage (100 mg b.i.d.) it boosted the levels of several
coadministered protease inhibitors to concentrations at which
antimalarial activity was seen (Table 1). Caution should be
exercised, however, as ritonavir’s potent inhibition of cytochrome P450 may lead to complex drug interactions in coinfected patients (4).
The predicted antimalarial mechanism of action of HIV-1
protease inhibitors is the inhibition of plasmepsins. The P.
falciparum genome predicts the existence of 10 plasmepsins.
The best characterized is plasmepsin II, an acidic food vacuole
enzyme that appears to play a role in the initial hydrolysis of

TABLE 1. Activity of HIV-1 protease inhibitors against cultured P. falciparumh
Serum concn (M) with:
P. falciparum IC50 (M) for:

Drug

Saquinavira
Ritonavirb
Indinavirc
Nelfinavird
Amprenavire
Lopinavirf
Atazanavirg

Standard dosing

Ritonavir
coadministration

HB3

D6

Dd2

W2

Cmax

Cmin

Cmax

Cmin

5.6 ⫾ 0.4
4.7 ⫾ 0.2
5.8 ⫾ 0.9
15.2 ⫾ 0.1
51.9 ⫾ 22.4
1.4 ⫾ 0.2
6.8 ⫾ 0.3

4.8 ⫾ 1.2
7.9 ⫾ 1.9
15.6 ⫾ 2.6
23.0 ⫾ 3.5
25.0 ⫾ 8.3
2.0 ⫾ 0.4
11.6 ⫾ 2.5

4.3 ⫾ 1.2
6.9 ⫾ 2.5
31.2 ⫾ 9.4
19.1 ⫾ 5.5
17.4 ⫾ 12.2
2.1 ⫾ 0.2
7.1 ⫾ 1.3

1.1 ⫾ 0.5
1.2 ⫾ 0.5
4.1 ⫾ 2.4
6.5 ⫾ 2.3
33.3 ⫾ 6.6
0.9 ⫾ 0.2
2.5 ⫾ 1.0

3.7
15.5
10.3
6.0
15.2
NA
3.3

0.3
5.1
0.3
3.3
0.6
NA
0.2

5.5
NA
17.2
NA
14.1
15.6
8.7

0.6
NA
0.4
NA
3.8
8.8
1.7

a
Based on saquinavir 1,200 mg three times daily (as free base) in HIV-infected individuals and coadministered saquinavir soft gel capsule 1,000 mg/ritonavir 100
mg b.i.d. in HIV-infected individuals (Roche prescribing information) (14).
b
Based on ritonavir 600 mg b.i.d. in healthy and HIV-infected individuals (Abbott prescribing information).
c
Based on indinavir sulfate 800 mg every 8 h and coadministered indinavir 800 mg/ritonavir 100 mg b.i.d. in healthy individuals with low-fat meal (3).
d
Based on nelfinavir mesylate 1,250 mg b.i.d. in HIV-infected individuals; Cmin was determined prior to morning dosage (Agouron prescribing information).
e
Based on amprenavir 1,200 mg b.i.d. in healthy individuals and coadministered amprenavir 600 mg/ritonavir 100 mg b.i.d. in HIV-infected individuals (GlaxoSmithKline prescribing information) (7).
f
Based on lopinavir 400 mg/ritonavir 100 mg b.i.d. in HIV-infected individuals (Abbott prescribing information).
g
Based on atazanavir sulfate 400 mg once a day (q.d.) in HIV-infected subjects and coadministered atazanavir 300 mg/ritonavir 100 mg q.d. (Bristol-Myers Squibb
prescribing information); serum concentrations are given as geometric means of atazanavir, as free base.
h
IC50 data are means ⫾ standard deviations from four experiments. Serum concentrations are from published information. Cmax and Cmin are the mean maximum
and minimum serum levels achieved under standard dosing intervals, respectively. Ritonavir-boosted serum concentrations are those achieved with coadministration
with ritonavir, as indicated in the other footnotes. NA, not applicable, as these formulations are not used clinically.
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FIG. 1. Effects of HIV-protease inhibitors on cultured parasites. A.
Parasite morphology. Synchronized ring stage parasites were incubated with 10 M lopinavir. Treated and control (with equivalent
concentrations of DMSO) parasites were evaluated at the indicated
time points on Giemsa-stained smears. B. Parasite development. Synchronized parasites were incubated with multiple concentrations of
lopinavir, beginning at the ring stage. After 48 h, ring parasitemias
were determined by flow cytometry analysis of YOYO-1-stained parasites, as previously described (11). Results represent two independent
experiments, each performed in duplicate using the HB3 strain of P.
falciparum. Error bars represent standard deviations.

hemoglobin by intraerythrocytic malaria parasites (2). To determine if HIV-1 protease inhibitors also inhibit the P. falciparum protease, the effects of lopinavir and ritonavir on the
hydrolysis of a hemoglobin-based peptide substrate by recombinant plasmepsin II were assessed. Plasmepsin II was expressed, purified, and studied as described previously, with the
exception that proplasmepsin II was preactivated for 60 min at
37°C, pH 5.2, and inhibitors were preincubated with enzyme
for 30 min prior to addition of 0.5 M substrate (2). Hydrolysis
was recorded as the increase in fluorescence over 10 minutes
using a Molecular Devices FlexStation II fluorometer. Both
tested protease inhibitors inhibited plasmepsin II at concentrations (IC50, 2.7 M for lopinavir and 3.1 M for ritonavir)
near those that were inhibitory for cultured malaria parasites.
However, it remains unclear if the protease inhibitors achieve
adequate intracellular concentrations to inhibit plasmepsin II,
and additional studies will be needed to fully characterize their
specific enzymatic targets.
Antiretroviral therapy is increasingly available to HIV-infected individuals in malaria-endemic regions. Currently, nonnucleoside reverse transcriptase inhibitor (NNRTI)-based regimens are preferred because of cost, simplicity of dosing,
modest storage requirements, and availability of coformulated
preparations (15). However, protease inhibitors are advocated
in some regions where the HIV type is insensitive to NNRTIs
and for the treatment of viruses that are resistant to other
classes of drugs. The use of protease inhibitors will likely increase as NNRTI resistance rises and as protease inhibitor
regimens are simplified (15).
Our results support the intriguing possibility that HIV-infected individuals receiving protease inhibitor therapy may
also benefit from an antimalarial effect due to inhibition of
plasmepsins. In vitro, lopinavir demonstrated potent activity
against P. falciparum at concentrations well below those
achievable with standard dosing of a ritonavir-boosted lopina-
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vir regimen. Due to concerns regarding cost, toxicity, and potential selection of resistant viruses, it is unlikely that currently
available HIV-1 protease inhibitors will gain roles as standard
treatments for malaria. Nonetheless, it seems likely that, for
select protease inhibitors, the concentrations achieved during
chronic antiretroviral therapy will offer some protection
against malaria. If standard regimens for HIV-1 offer chemoprophylaxis against malaria, particularly in children, in whom
the burden of malaria is greatest, the clinical consequences of
this effect will be great. However, it is unclear if in vitro results
showing antimalarial activity of HIV-1 protease inhibitors predict clinical efficacy. Therefore, clinical trials to test the hypothesis that HIV-1 protease inhibitors confer protection
against malaria are urgently needed.
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